Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.77 USD

1.77
1,216,822

+0.20 (12.74%)

Updated May 31, 2024 04:00 PM ET

After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates

AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.

LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise

LabCorp (LH) registered year-over-year growth in operating segments in Q4.

Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates

Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources

The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources

CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve

CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

Tirthankar Chakraborty headshot

Virus or No Virus, Investing Case in US Stocks Looks Solid!

U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.

Radware (RDWR) Q4 Earnings and Revenues Miss Estimates

Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4

Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

DaVita (DVA) gains from dialysis services in the United States in Q4.

STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View

STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.

Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y

Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2

We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

Cerner (CERN) Earnings and Revenues Beat Estimates in Q4

Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.

Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow

Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.

Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y

Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.